Update: Visitect variability vanquished
Omega’s FY15 trading update reported that the Visitect CD4 test for HIV monitoring is making “good†progress with management “very confident†that the test variability causes can be resolved. Customer site evaluations on allergy iSYS (using 27 optimised allergens) are being planned to lead towards product launch. For FY15, management guides about 27% growth in adjusted PBT to about £1.4m on overall test sales of £12.1m, up 4%. Food intolerance performed well with 15% growth; manual allergy sales were down 9%, but there was some growth in infectious disease, up 4% after a long period of decline. Mr Colin King is joining as COO on 3 August.Omega Diagnostics Group is a holding company. Through its subsidiaries, Co. is engaged in the manufacturing, development and distribution of medical diagnostics products. Co. has three operating divisions: Allergy and autoimmune, which in the research, development, production and marketing of in-vitro allergy and autoimmune tests; Food intolerance, which provides clinical analysis to the general public, clinics and health professionals as well as supplying the consumer; and Infectious disease and Other, which comprise of research, development, production and marketing of kits to aid the diagnosis of infectious diseases.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.